Loading...
Please wait, while we are loading the content...
Similar Documents
Use of 68Ga DOTATATE, a new molecular imaging agent, for neuroendocrine tumors.
| Content Provider | Scilit |
|---|---|
| Author | Leblanc, Raymond Andrew Oza, Umesh D. Hayden, Ryan Fanous, Hanna |
| Copyright Year | 2019 |
| Description | Neuroendocrine tumors (NET), such as insulinomas and carcinoid tumors, can be challenging to diagnose since patients often present with vague symptoms. Adding to the challenge, these tumors are often occult on typical cross-sectional imaging modalities. Because of these challenges, there has been an increase in the utilization of radiopharmaceuticals that take advantage of specific receptors expressed by NET. Among the multiple radiopharmaceuticals that can be used,$ ^{68}$Ga DOTATATE is emerging as the most sensitive and specific imaging agent. We present a case where$ ^{68}$Ga DOTATATE was used to diagnose a well-differentiated neuroendocrine tumor. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988632/pdf |
| Ending Page | 52 |
| Page Count | 2 |
| Starting Page | 51 |
| ISSN | 08998280 |
| e-ISSN | 15253252 |
| DOI | 10.1080/08998280.2019.1678338 |
| Journal | Baylor University Medical Center Proceedings |
| Issue Number | 1 |
| Volume Number | 33 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2019-11-04 |
| Access Restriction | Open |
| Subject Keyword | Medical Laboratory Technology Neuroimaging Carcinoid 68ga Dotatate F-18 Fludeoxyglucose Neuroendocrine Tumors Positron Emission Tomography/computed Tomography |
| Content Type | Text |
| Resource Type | Article |
| Subject | Medicine |
